ARTICLE | Financial News

Clinical hold sinks Advaxis shares

March 13, 2018 5:07 PM UTC

Advaxis Inc. (NASDAQ:ADXS) tumbled $0.26 (12%) to $1.95 on Tuesday after the company announced late Monday that FDA had placed a clinical hold on a Phase I/II trial of axalimogene filolisbac (ADXS11-001) (see BioCentury Extra, March 12). ...

BCIQ Company Profiles

Advaxis Inc.

AstraZeneca plc